URGN vs. VRTX
URGN (UroGen Pharma Ltd.) and VRTX (Vertex Pharmaceuticals Incorporated) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, URGN returned 15.86%/yr vs 20.01%/yr for VRTX. At a 0.24 correlation, their price movements are largely independent.
Performance
URGN vs. VRTX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, URGN achieves a 49.40% return, which is significantly higher than VRTX's 2.96% return.
URGN
- 1D
- 4.23%
- 1M
- 21.11%
- YTD
- 49.40%
- 6M
- 48.39%
- 1Y
- 138.84%
- 3Y*
- 45.07%
- 5Y*
- 15.86%
- 10Y*
- —
VRTX
- 1D
- 3.36%
- 1M
- 7.43%
- YTD
- 2.96%
- 6M
- 1.41%
- 1Y
- 5.88%
- 3Y*
- 10.39%
- 5Y*
- 20.01%
- 10Y*
- 19.01%
URGN vs. VRTX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
URGN UroGen Pharma Ltd. | 49.40% | 119.91% | -29.00% | 69.11% | -6.73% | -47.23% | -46.00% | -22.50% | 15.72% | 179.98% |
VRTX Vertex Pharmaceuticals Incorporated | 2.96% | 12.58% | -1.03% | 40.90% | 31.50% | -7.08% | 7.94% | 32.13% | 10.58% | 25.88% |
Correlation
The correlation between URGN and VRTX is 0.25, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.25 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.21 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.22 |
Correlation (All Time) Calculated using the full available price history since May 4, 2017 | 0.24 |
Fundamentals
URGN:
$1.76B
VRTX:
$119.64B
URGN:
-$2.73
VRTX:
$16.87
URGN:
12.15
VRTX:
9.80
URGN:
$140.49M
VRTX:
$12.26B
URGN:
$126.24M
VRTX:
$10.57B
URGN:
-$117.04M
VRTX:
$5.19B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
URGN vs. VRTX — Risk / Return Rank
URGN
VRTX
URGN vs. VRTX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for UroGen Pharma Ltd. (URGN) and Vertex Pharmaceuticals Incorporated (VRTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| URGN | VRTX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.90 | ||
| Sortino ratioReturn per unit of downside risk | +2.25 | ||
| Omega ratioGain probability vs. loss probability | 1.32 | 1.07 | +0.25 |
| Calmar ratioReturn relative to maximum drawdown | 3.31 | 0.25 | +3.06 |
| Martin ratioReturn relative to average drawdown | 6.87 | 0.52 | +6.35 |
Loading charts...
Drawdowns
URGN vs. VRTX - Drawdown Comparison
The maximum URGN drawdown since its inception was -93.98%, roughly equal to the maximum VRTX drawdown of -91.77%. Use the drawdown chart below to compare losses from any high point for URGN and VRTX.
Loading charts...
Drawdown Indicators
| URGN | VRTX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.98% | -91.77% | -2.21% |
Max Drawdown (1Y)Largest decline over 1 year | -42.22% | -23.56% | -18.66% |
Max Drawdown (3Y)Largest decline over 3 years | -82.64% | -29.07% | -53.57% |
Max Drawdown (5Y)Largest decline over 5 years | -82.64% | -29.07% | -53.57% |
Max Drawdown (10Y)Largest decline over 10 years | — | -41.60% | — |
Current DrawdownCurrent decline from peak | -46.44% | -9.67% | -36.77% |
Average DrawdownAverage peak-to-trough decline | -61.48% | -37.72% | -23.76% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 20.32% | 11.35% | +8.97% |
Volatility
URGN vs. VRTX - Volatility Comparison
UroGen Pharma Ltd. (URGN) has a higher volatility of 12.68% compared to Vertex Pharmaceuticals Incorporated (VRTX) at 7.71%. This indicates that URGN's price experiences larger fluctuations and is considered to be riskier than VRTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| URGN | VRTX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.68% | 7.71% | +4.97% |
Volatility (6M)Calculated over the trailing 6-month period | 44.04% | 21.02% | +23.02% |
Volatility (1Y)Calculated over the trailing 1-year period | 67.38% | 34.25% | +33.13% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 91.62% | 28.57% | +63.05% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 79.43% | 32.82% | +46.61% |
Dividends
URGN vs. VRTX - Dividend Comparison
Neither URGN nor VRTX has paid dividends to shareholders.
Financials
URGN vs. VRTX - Financials Comparison
This section allows you to compare key financial metrics between UroGen Pharma Ltd. and Vertex Pharmaceuticals Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
URGN vs. VRTX - Profitability Comparison
URGN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, UroGen Pharma Ltd. reported a gross profit of 46.82M and revenue of 50.96M. Therefore, the gross margin over that period was 91.9%.
VRTX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Vertex Pharmaceuticals Incorporated reported a gross profit of 2.59B and revenue of 2.99B. Therefore, the gross margin over that period was 86.9%.
URGN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, UroGen Pharma Ltd. reported an operating income of -20.26M and revenue of 50.96M, resulting in an operating margin of -39.8%.
VRTX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Vertex Pharmaceuticals Incorporated reported an operating income of 1.14B and revenue of 2.99B, resulting in an operating margin of 38.1%.
URGN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, UroGen Pharma Ltd. reported a net income of -23.57M and revenue of 50.96M, resulting in a net margin of -46.3%.
VRTX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Vertex Pharmaceuticals Incorporated reported a net income of 1.03B and revenue of 2.99B, resulting in a net margin of 34.5%.
Frequently Asked Questions
URGN and VRTX have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
URGN has higher volatility (12.68%) compared to VRTX (7.71%). In terms of maximum drawdown, URGN dropped -93.98% vs VRTX's -91.77%.
URGN currently has the higher Sharpe Ratio (2.08 vs 0.17), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for URGN and VRTX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer